Table 1 Demographic and Clinical Characteristics by Regimen Group
Regimen A (N = 66) | Regimen B (N = 25) | Regimen C (N = 56) | Total (n = 147) | |
|---|---|---|---|---|
Age, mean (SD) | 64.5 (11.11) | 67.4 (12.96) | 64.1 (9.62) | 64.8 (10.90) |
Gender | ||||
Male | 33 (50.0%) | 17 (68.0%) | 36 (64.3%) | 86 (58.5%) |
Female | 33 (50.0%) | 8 (32.0%) | 20 (35.7%) | 61 (41.5%) |
Race* | ||||
White or Caucasian | 57 (86.4%) | 17 (68.0%) | 53 (94.6%) | 127 (86.4%) |
Black or African American | 6 (9.1%) | 6 (24.0%) | 2 (3.6%) | 14 (9.5%) |
Other races | 3 (4.5%) | 2 (8.0%) | 1 (1.8%) | 6 (4.1%) |
Body Mass Index, mean (SD) (N = 146) | 26.0 (5.40) | 25.4 (5.81) | 25.8 (4.37) | 25.8 (5.07) |
Geographic Region* | ||||
Midwest | 10 (15.2%) | 7 (28.0%) | 16 (28.6%) | 33 (22.4%) |
Northeast | 12 (18.2%) | 0 (0.0%) | 8 (14.3%) | 20 (13.6%) |
South | 38 (57.6%) | 18 (72.0%) | 25 (44.6%) | 81 (55.1%) |
West | 6 (9.1%) | 0 (0.0%) | 7 (12.5%) | 13 (8.8%) |
Stage at Initial Diagnosis | ||||
I | 5 (7.5%) | 1 (4.0%) | 3 (5.4%) | 9 (6.1%) |
II | 2 (3.0%) | 0 (0.0%) | 2 (3.6%) | 4 (2.7%) |
III | 4 (6.0%) | 3 (12.0%) | 5 (9.0%) | 12 (8.1%) |
IV | 52 (78.8%) | 21 (84.0%) | 46 (82.1%) | 119 (81.0%) |
Unknown/Not documented | 3 (4.5%) | 0 (0.0%) | 0 (0.0%) | 3 (2.0%) |
Performance Status (ECOG 2+ or equivalent) a | ||||
Impaired | 6 (9.1%) | 5 (20.0%) | 9 (16.1%) | 20 (13.6%) |
Not impaired, or not indicated as impaired | 60 (90.9%) | 20 (80.0%) | 47 (83.9%) | 127 (86.4%) |
Sites of Metastatic Disease at Baseline | ||||
Bone | 29 (43.9%) | 8 (32.0%) | 20 (35.7%) | 57 (38.8%) |
Brain | 11 (16.7%) | 4 (16.0%) | 17 (30.4%) | 32 (21.8%) |
Liver | 12 (18.2%) | 3 (12.0%) | 10 (17.9%) | 25 (17.0%) |
Comorbidityb | ||||
Any | 32 (48.5%) | 14 (56.0%) | 35 (62.5%) | 81 (55.1%) |
Alzheimer’s or other dementia | 0 (0.0%) | 1 (4.0%) | 0 (0.0%) | 1 (0.7%) |
Cerebrovascular accident | 3 (4.5%) | 2 (8.0%) | 7 (12.5%) | 12 (8.2%) |
COPD | 20 (30.3%) | 10 (40.0%) | 19 (33.9%) | 49 (33.3%) |
Cirrhosis | 2 (3.0%) | 1 (4.0%) | 0 (0.0%) | 3 (2.0%) |
Congestive heart failure | 2 (3.0%) | 1 (4.0%) | 3 (5.4%) | 6 (4.1%) |
Connective tissue disease | 4 (6.1%) | 0 (0.0%) | 3 (5.4%) | 7 (4.8%) |
Diabetes | 4 (6.1%) | 4 (16.0%) | 13 (23.2%) | 21 (14.3%) |
Metastatic solid tumor | 1 (1.5%) | 2 (8.0%) | 1 (1.8%) | 4 (2.7%) |
Myocardial infarction | 2 (3.0%) | 1 (4.0%) | 4 (7.1%) | 7 (4.8%) |
Peripheral vascular disease | 4 (6.1%) | 2 (8.0%) | 6 (10.7%) | 12 (8.2%) |
Renal disease | 5 (7.6%) | 2 (8.0%) | 2 (3.6%) | 9 (6.1%) |
Ulcer disease | 0 (0.0%) | 1 (4.0%) | 2 (3.6%) | 3 (2.0%) |
Weighted Comorbidity Index (Mean ± SD) | 0.9 ± 1.35 | 1.6 ± 2.53 | 1.2 ± 1.44 | 1.1 ± 1.65 |
Radiation Therapy in Advanced Setting* | 8 (12.1%) | 4 (16.0%) | 23 (41.1%) | 35 (23.8%) |
Smoking Status | ||||
Current | 11 (16.7%) | 6 (24.0%) | 15 (26.8%) | 32 (21.8%) |
Past | 50 (75.8%) | 17 (68.0%) | 36 (64.3%) | 103 (70.1%) |
Never smoked | 4 (6.1%) | 1 (4.0%) | 5 (8.9%) | 10 (6.8%) |
Unknown | 1 (1.5%) | 1 (4.0%) | 0 (0.0%) | 2 (1.4%) |